# Metabolomic profiles and health-promoting potential of Euchresta japonica tissues revealed by widely targeted metabolomics

**Authors:** Liai Xu, Xi Liu, Xiangdong Pan, Sinan Xu, Qinglian Wu, Chengyi Ma, Zupei Lei, Yeqing Ying

PMC · DOI: 10.3389/fpls.2025.1537273 · Frontiers in Plant Science · 2025-05-01

## TL;DR

This study identifies over 2,000 metabolites in Euchresta japonica, revealing its medicinal potential, especially in lateral roots and inflorescences.

## Contribution

The study provides the first comprehensive metabolomic profile of E. japonica and identifies key tissues and pathways with therapeutic potential.

## Key findings

- E. japonica contains 2,140 metabolites, including 305 key active ingredients and 364 pharmaceutical ingredients for nine diseases.
- Lateral roots and inflorescences are the richest sources of bioactive metabolites.
- Flavonoid biosynthesis pathways are central to the plant's medicinal potential.

## Abstract

Euchresta japonica, a medicinal plant in Chinese herbal medicine, lacks comprehensive metabolite data to explain its health benefits despite its long-standing use. Here, widely targeted metabolome at six different tissues of E. japonica was investigated, identifying 2,140 metabolites, including flavonoids, phenolic acids, amino acids, lipids, and alkaloids. Among them, 305 were annotated as key active ingredients, and 364 were active pharmaceutical ingredients for nine human disease-resistance, with 206 co-annotated. Metabolic profiles varied significantly across tissues, with medicinally active metabolites highly concentrated in lateral roots and inflorescences, indicating great medical potential. Notably, the lateral root, rather than the main root, was the primary source of root-derived bioactive metabolites. Additionally, KEGG analysis demonstrated that secondary metabolic pathways, especially “isoflavonoid biosynthesis” and “flavonoid biosynthesis” pathways, played important roles. Overall, lateral roots and inflorescences exhibit the strongest potential for disease treatment, particularly for chronic and multifactorial diseases. This study significantly advances our understanding of E. japonica’s chemical composition and underscores its potential as a valuable resource for novel therapeutic applications, providing a strong foundation for further investigation into its pharmacological properties and drug development prospects.

## Linked entities

- **Species:** Euchresta japonica (taxon 256639)

## Full-text entities

- **Genes:** PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}
- **Diseases:** throat (MESH:C538390), esophageal cancer (MESH:D004938), diarrhea (MESH:D003967), hepatocellular carcinoma (MESH:D006528), heart stroke (MESH:D006331), cancer (MESH:D009369), abdominal pain (MESH:D015746), metastasis (MESH:D009362), myocardial infarction (MESH:D009203), depression (MESH:D003866), colorectal cancer (MESH:D015179), inflammation (MESH:D007249), fibrosis (MESH:D005355), pain (MESH:D010146), cardiometabolic diseases (MESH:D024821), hypertension (MESH:D006973), stroke (MESH:D020521), coronary heart disease (MESH:D003327), sore throats (MESH:D010612), Alzheimer (MESH:D000544), stomach pain (MESH:D013272), arthritis (MESH:D001168), diabetes (MESH:D003920), OB (MESH:D020820), nociceptive (MESH:D059226), toothache (MESH:D014098), angina pectoris (MESH:D000787), cardiovascular disease (MESH:D002318), platelet aggregation (MESH:D001791), gastrointestinal, neuropsychological, metabolic, and cardiovascular disorders (MESH:D005767), DL (MESH:D056486), chronic (MESH:D002908), enteritis (MESH:D004751), breast, colorectal, lung, bladder, prostate, and ovarian cancers (MESH:D010051), Parkinson's disease (MESH:D010300), osteoarthritis (MESH:D010003), alcoholism (MESH:D000437), anxiety disorders (MESH:D001008), sexual dysfunction (MESH:D012735), Schizophrenia (MESH:D012559), gestational hypertension (MESH:D046110), osteoporosis (MESH:D010024), insomnia (MESH:D007319)
- **Chemicals:** adenosine (MESH:D000241), starch (MESH:D013213), Lignans (MESH:D017705), syringin (MESH:C028305), alanine (MESH:D000409), diphyllin (MESH:C010130), ascorbate (MESH:D001205), fargesin (MESH:C539377), moupinamide (MESH:C074004), beta-isosparteine (MESH:D013034), formic acid (MESH:C030544), reactive oxygen species (MESH:D017382), punicic acid (MESH:C519714), sesamin (MESH:C054125), isoflavones (MESH:D007529), uridine 5'-monophosphate (MESH:D014542), glycyrin (MESH:C000602096), lauroscholtzine (MESH:C000600631), Ferulic acid (MESH:C004999), lactones (MESH:D007783), diterpenoids (MESH:D004224), Nobiletin (MESH:C008661), steroid (MESH:D013256), Isovitexin (MESH:C049772), Taxifolin (MESH:C003377), glucuronate (MESH:D020723), K+ (MESH:D011188), Icaritin (MESH:C499403), Wogonin (MESH:C085514), galactose (MESH:D005690), 5-hydroxy-L-tryptophan (MESH:D006916), embelin (MESH:C010945), sucrose (MESH:D013395), acetonitrile (MESH:C032159), Epicatechin gallate (MESH:C062669), linoleic acid (MESH:D019787), flavones (MESH:D047309), emodin-8-O-glucoside (MESH:C442642), Amino acids (MESH:D000596), Glycitein (MESH:C086566), Coumestrol (MESH:D003375), Kaempferol (MESH:C006552), Genkwanin (MESH:C014568), Luteolin (MESH:D047311), dalbergin (MESH:C000613895), 9-hydroxy-10,12,15-octadecatrienoic acid (MESH:C062142), Tannins (MESH:D013634), pyruvate (MESH:D019289), Calycosin (MESH:C121707), pinolenic acid (MESH:C034302), triterpenes (MESH:D014315), chalcones (MESH:D047188), flemiphilippinin C (MESH:C070776), vitamin K1 (MESH:D010837), p-coumaroyltyramine (MESH:C001411), alpha-linolenic acid (MESH:D017962), ellagic acid (MESH:D004610), L-histidine (MESH:D006639), carbon (MESH:D002244), Didymin (MESH:C552234)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Astragalus membranaceus (species) [taxon 649199], Sophora flavescens (species) [taxon 49840], E. japonica [taxon 160899], Eriobotrya japonica (loquat, species) [taxon 32224], Euchresta japonica (species) [taxon 256639], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12078262/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12078262/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12078262/full.md

---
Source: https://tomesphere.com/paper/PMC12078262